Clinical trialNCT04260698CompletedPhase 3Interventional

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

SponsorGamida Cell ltdEnrollment36Hematological Malignancies

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mitchell Horwitz, MD
Duke University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucla
Los Angeles, California, United States
Stanford University Cancer Institute
Palo Alto, California, United States
Loyola University, Cardinal Bernardin Cancer Center
Maywood, Illinois, United States
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
Duke University Medical Center
Durham, North Carolina, United States
Oregon Health & Science University
Portland, Oregon, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Omidubicel

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Jul 2020
Primary completion: 8 May 2025
Completion: 8 May 2025
Last update posted: 22 Jun 2026
Registered enrollment: 36
Registry id: NCT04260698

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.